Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. KORU Medical Systems's selling, general, & admin. expense for the
three
months ended in Jun. 2026 was $5.94 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2026 was $24.56 Mil.
KORU Medical Systems (NAS:KRMD) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
KORU Medical Systems Selling, General, & Admin. Expense Related Terms
KORU Medical Systems Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for KORU Medical Systems's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KORU Medical Systems Selling, General, & Admin. Expense Chart
KRMD vs PDEX, EMBC, UTMD: Selling, General, & Admin. Expense Comparison
For the Medical Instruments & Supplies subindustry, KORU Medical Systems's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KORU Medical Systems Selling, General, & Admin. Expense vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where KORU Medical Systems's Selling, General, & Admin. Expense falls into.
KORU Medical Systems Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of $24.56 Mil mean?
KORU Medical Systems (KRMD) has a Selling, General, & Admin. Expense of $24.56 Mil as of Jun. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on KORU Medical Systems and its competitors.
Is KORU Medical Systems' Selling, General, & Admin. Expense too high?
KORU Medical Systems' current Selling, General, & Admin. Expense is $24.56 Mil. Overall, KORU Medical Systems has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does KORU Medical Systems' Selling, General, & Admin. Expense compare to PDEX and EMBC?
KORU Medical Systems' Selling, General, & Admin. Expense of $24.56 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Devices & Instruments company?
A good Selling, General, & Admin. Expense depends on the Medical Devices & Instruments industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on KORU Medical Systems and its competitors. KORU Medical Systems's current Selling, General, & Admin. Expense is $24.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KORU Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, KORU Medical Systems (KRMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.01, compared to a current price of $3.40 — trading 15.2% below its estimated fair value. The current Selling, General, & Admin. Expense is $24.56 Mil. KORU Medical Systems' overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For KORU Medical Systems (KRMD), the current Selling, General, & Admin. Expense is $24.56 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KORU Medical Systems (KRMD) Overvalued in 2026?
Based on GuruFocus' analysis, KORU Medical Systems stock appears to be undervalued.
The current stock price of $3.40 is trading 15.2% below its estimated GF Value™ of $4.01.
GuruFocus considers KORU Medical Systems to be Modestly Undervalued.
Key valuation signals for KRMD:
Selling, General, & Admin. Expense: $24.56 Mil
GF Value™: $4.01 vs. price of $3.40 (15.2% below fair value)
No single metric tells the full story. See the KRMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
80GF Score
Get the complete analysis for KRMD
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KRMD has been successfully added to your 
